Overview

Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
0
Participant gender:
All
Summary
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to therapy than the current standard of care (CT or MRI).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Stanford University
Collaborator:
National Comprehensive Cancer Network
Treatments:
Fluorodeoxyglucose F18
Sunitinib
Criteria
Inclusion Criteria:- Measurable disease by RECIST criteria

- Pathologic diagnosis of renal cell cancer

- Advanced (stage IV) renal cell cancer

- Karnofsky performance status of (KPS>70)

- Consent to participate in the clinical trial Exclusion Criteria:- Patients who cannot
complete a PET/CT scan.

- Pregnant women.

- Healthy volunteers.

- Patients participating in other research protocols will be excluded from this study.

- Metallic implants (prosthesis, ICD, pacemakers), since these are contraindications for
MRI.